18A184

About Atlanthera

Atlanthera is a privately held, pre-clinical stage biotech company developing targeted therapies for bone and joint diseases. Its core technology involves conjugating active pharmaceutical ingredients (APIs) to proprietary hydroxybisphosphonate (HBP) vectors, enabling selective drug delivery to bone tissue to improve efficacy and reduce systemic toxicity. The company's pipeline includes candidates for osteosarcoma, osteoarthritis, and bone metastases, with its lead program nearing clinical entry. Atlanthera operates with a lean team and seeks partnerships for clinical development and commercialization.

Therapeutic Areas